Literature DB >> 1512549

T cell lines characterize events in the pathogenesis of the Wiskott-Aldrich syndrome.

I J Molina1, D M Kenney, F S Rosen, E Remold-O'Donnell.   

Abstract

The Wiskott-Aldrich syndrome (WAS) is a severe immunodeficiency and platelet deficiency disease arising from an X-linked defect. The disease is correctable by transplantation of hematopoietic stem cells, but the product of the defective gene is unidentified and the number of defects in patient blood cells is large. The current hurdle is the need to identify the early pathogenic event(s) that are the cause of other defects. As a step toward this goal, we have generated and examined a panel of interleukin 2-dependent allospecific T cell lines from peripheral lymphocytes of seven WAS patients and five normal individuals. WAS cell lines, like normal lines, undergo vigorous proliferation when challenged with specific allostimulant or with phorbol myristate acetate and ionomycin. Both normal and WAS T cell lines express cell surface molecules CD2, CD3, T cell receptor-alpha/beta, human histocompatibility leukocyte antigen class I, CD45 and CD11a, and varying ratios of CD4 and CD8, and are negative for natural killer cell and monocyte surface molecules. WAS T cell lines express CD43 (sialophorin/leukosialin) with molecular weight and in an amount comparable with normal T cell lines. WAS T cell lines thus do not express defects in CD43 (decreased amount, abnormal molecular weight), previously documented in WAS circulating lymphocytes. On the other hand, as detected by scanning electron microscopy, WAS cell lines exhibit severe morphological abnormalities, including decreased size and density of the microvillus surface projections. The morphological abnormalities of WAS T cell lines are similar to, or more extensive than, those previously reported for WAS peripheral lymphocytes, indicating that the generation of morphological (cytoarchitectural) defects is an early pathogenic event in this disease. The findings suggest that the gene that is defective in the WAS encodes a protein that normally functions to maintain or regulate the cytoskeletal structure of blood cells.

Entities:  

Mesh:

Year:  1992        PMID: 1512549      PMCID: PMC2119357          DOI: 10.1084/jem.176.3.867

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Molecular heterogeneity of a lymphocyte glycoprotein in immunodeficient patients.

Authors:  D Reisinger; R Parkman
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

2.  Preliminary structural characterization of the leukocyte cell surface molecule recognized by monoclonal antibody TA-1.

Authors:  T W LeBien; J G Bradley; B Koller
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

Review 3.  The primary immunodeficiencies. (2).

Authors:  F S Rosen; M D Cooper; R J Wedgwood
Journal:  N Engl J Med       Date:  1984-08-02       Impact factor: 91.245

4.  Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions.

Authors:  S C Meuer; S F Schlossman; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

5.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

6.  Characterization of a membrane surface glycoprotein associated with T-cell activation.

Authors:  J R Sportsman; M M Park; D A Cheresh; M Fukuda; J H Elder; R I Fox
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

7.  A human leukocyte antigen identified by a monoclonal antibody.

Authors:  A E Berger; J E Davis; P Cresswell
Journal:  Hum Immunol       Date:  1981-11       Impact factor: 2.850

8.  Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation.

Authors:  R Parkman; J Rappeport; R Geha; J Belli; R Cassady; R Levey; D G Nathan; F S Rosen
Journal:  N Engl J Med       Date:  1978-04-27       Impact factor: 91.245

9.  Human neutrophil Fc gamma receptor distribution and structure.

Authors:  H B Fleit; S D Wright; J C Unkeless
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

10.  Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16.

Authors:  A Pallant; A Eskenazi; M G Mattei; R E Fournier; S R Carlsson; M Fukuda; J G Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

View more
  30 in total

Review 1.  The Wiskott-Aldrich syndrome.

Authors:  A J Thrasher; C Kinnon
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

Review 2.  Wiskott-Aldrich syndrome: another piece in the puzzle.

Authors:  L D Notarangelo; L Mori
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

Review 3.  The Wiskott-Aldrich syndrome.

Authors:  H D Ochs
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Leukocyte polarization in cell migration and immune interactions.

Authors:  F Sánchez-Madrid; M A del Pozo
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

Review 5.  Insights into primary immune deficiency from quantitative microscopy.

Authors:  Emily M Mace; Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2015-06-13       Impact factor: 10.793

6.  A congenital activating mutant of WASp causes altered plasma membrane topography and adhesion under flow in lymphocytes.

Authors:  Siobhan O Burns; David J Killock; Dale A Moulding; Joao Metelo; Joao Nunes; Ruth R Taylor; Andrew Forge; Adrian J Thrasher; Aleksandar Ivetic
Journal:  Blood       Date:  2010-03-30       Impact factor: 22.113

7.  Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome.

Authors:  Taizo Wada; Shepherd H Schurman; Elizabeth K Garabedian; Akihiro Yachie; Fabio Candotti
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

8.  Studies of the expression of the Wiskott-Aldrich syndrome protein.

Authors:  D M Stewart; S Treiber-Held; C C Kurman; F Facchetti; L D Notarangelo; D L Nelson
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Direct interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42.

Authors:  R Kolluri; K F Tolias; C L Carpenter; F S Rosen; T Kirchhausen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

Review 10.  Wiskott-Aldrich Syndrome: Immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation.

Authors:  Gerben Bouma; Siobhan O Burns; Adrian J Thrasher
Journal:  Immunobiology       Date:  2009-07-22       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.